When immune cells from the tumor-regressed mice following treatment with gemcitabine were stimulated in vitro with HER2 class I peptides, they failed to produce IFN-γ to a significant level in response to HER2 class I peptides compared with control peptides (Figure 10B). Here, ERBB2 is linked to neoplasm.